Gabriele S Merki-Feld1, Martin Hund. 1. Clinic for Reproductive Endocrinology, Department of Gynaecology and Obstetrics, University Hospital, Zurich, Switzerland.
Abstract
OBJECTIVES: To assess clinical experience with NuvaRing in daily practice in Switzerland, including a large subgroup of young women (aged < or = 22 years). METHODS: Open, prospective, multicentre, observational clinical experience study to investigate cycle control, acceptability and usage of NuvaRing. RESULTS: Altogether, 2642 women participated in the programme and were included in the analysis, of which 658 were aged < or = 22 years (25% of the total group). A total of 744 women (28% of the total group) discontinued NuvaRing use; the main reason was adverse events (11% of all users). In younger women, there was a shift from moderate (-18%) and heavy (-45%) bleeding to mild bleeding (+71%) and dysmenorrhoea decreased by 60%, despite previous hormonal contraception use by 83% of women. Most women found ring insertion and removal to be straightforward (>95%), and were satisfied with its use (85%), primarily for the ring's once-a-month application (81%). Data were very similar for the total group. Cycle control and satisfaction were further improved with duration of treatment. CONCLUSIONS: In daily practice, NuvaRing improved cycle control and was highly acceptable to women, including young women. Switchers from other hormonal methods also showed improved cycle control and high satisfaction.
OBJECTIVES: To assess clinical experience with NuvaRing in daily practice in Switzerland, including a large subgroup of young women (aged < or = 22 years). METHODS: Open, prospective, multicentre, observational clinical experience study to investigate cycle control, acceptability and usage of NuvaRing. RESULTS: Altogether, 2642 women participated in the programme and were included in the analysis, of which 658 were aged < or = 22 years (25% of the total group). A total of 744 women (28% of the total group) discontinued NuvaRing use; the main reason was adverse events (11% of all users). In younger women, there was a shift from moderate (-18%) and heavy (-45%) bleeding to mild bleeding (+71%) and dysmenorrhoea decreased by 60%, despite previous hormonal contraception use by 83% of women. Most women found ring insertion and removal to be straightforward (>95%), and were satisfied with its use (85%), primarily for the ring's once-a-month application (81%). Data were very similar for the total group. Cycle control and satisfaction were further improved with duration of treatment. CONCLUSIONS: In daily practice, NuvaRing improved cycle control and was highly acceptable to women, including young women. Switchers from other hormonal methods also showed improved cycle control and high satisfaction.
Authors: Kathleen Ridgeway; Elizabeth T Montgomery; Kevin Smith; Kristine Torjesen; Ariane van der Straten; Sharon L Achilles; Jennifer B Griffin Journal: Contraception Date: 2021-10-10 Impact factor: 3.051
Authors: Suchitra N Pandit; Anahita R Chauhan; Manjula Anagani; Sanjeeva Reddy; Ashish Birla; Subrat K Ray Journal: J Obstet Gynaecol India Date: 2014-05-15
Authors: Kate Morrow Guthrie; Sara Vargas; Julia G Shaw; Rochelle K Rosen; Jacob J van den Berg; Patrick F Kiser; Karen Buckheit; Dana Bregman; Lara Thompson; Kathleen Jensen; Todd Johnson; Robert W Buckheit Journal: PLoS One Date: 2015-12-22 Impact factor: 3.240